Priya V. Shanmugam

Priya V. Shanmugam

Auto-generated profile, based on publicly available information

Priya V. Shanmugam

Research Department, Virta Health, Denver, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2026 in Public Health Reports®
Verified
Journal Article
Closed access
SCSaumya Chatrath
Saumya Chatrath
AKAmanda Kudis
Amanda Kudis
PSPriya Shanmugam
Priya Shanmugam
CBChase Barham
Chase Barham
CCClaire Coles
Claire Coles
JKJulie Kable
Julie Kable
Objectives: Fetal alcohol syndrome (FAS) is frequently undiagnosed or misdiagnosed, particularly among populations at elevated risk of the condition. We examined the prevalence of FAS among children aged 0 to 5 years enrolled in Medicaid, described characteristics of affected children, and evaluated diagnostic timing between children in foster care and children not in foster care. Methods: We conducted a retrospective analysis of Medicaid Transformed Analytic Files for children born from 2015 through 2017 with FAS diagnoses (n = 771), following each birth cohort for 5 years. We used descriptive statistics to examine prevalence rates and demographic characteristics. Multivariate linear regression models assessed differences in diagnostic timing between children in foster care and children not in foster care, controlling for demographic factors. Results: The overall FAS prevalence per 100 000 children aged 0 to 5 years enrolled in Medicaid was 7.7, increasing from 5.1 in 2015 to 11.4 in 2017. Children in foster care represented 60.2% (n = 464) of the FAS cohort. Although behavioral assessments occurred at similar ages for both groups, children in foster care received FAS diagnoses 4.6 to 5.4 months later than children not in foster care ( P < .001). The time between the first behavioral assessment and FAS diagnosis was 2.1 to 3.9 months longer for children in foster care than for children not in foster case. Conclusions: Children in foster care had substantial delays in diagnosis compared with children not in foster care. Initial access to behavioral assessment appears equitable; however, barriers exist in the progression from assessment to diagnosis for children in foster care. Implementing targeted screening protocols, improving cross-system information sharing, and enhancing health care provider training could reduce diagnostic delays and improve outcomes for this population.

11 August 2026 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
PSPriya V. Shanmugam
Priya V. Shanmugam
RARebecca N. Adams
Rebecca N. Adams
Shaminie AthinarayananShaminie Athinarayanan
Shaminie Athinarayanan
AWAdam J. Wolfberg
Adam J. Wolfberg
JBJeromie M. Ballreich
Jeromie M. Ballreich
Introduction Type 2 diabetes (T2D) and obesity are associated with substantial morbidity and healthcare spending. Although telehealth-delivered lifestyle interventions have demonstrated clinical benefits, evidence on their impact on healthcare costs and utilization remains limited. This study evaluated the association between participation in a comprehensive nutrition-first digital care model integrating individualized carbohydrate-reduced nutrition support, clinician-guided medication management, health coaching, and remote biometric monitoring on total healthcare costs and utilization over 1 year and 2 years. Methods We conducted a claims-based, retrospective propensity score matched difference-in-differences analysis of cost and utilization outcomes among US adults with T2D or obesity who (1) enrolled in Virta Health’s Individualized Nutrition Therapy (INT) program or (2) had a primary care visit for either condition between 2017 and 2025. Per-member, per-month (PMPM) outcomes included inpatient, outpatient, and prescription medication costs, as well as inpatient, emergency department, primary care, cardiology, and endocrinology visits. For the T2D cohort only, PMPM costs for each diabetes medication were also evaluated. Results Among 3819 adults with T2D and 2761 adults with obesity, program participation was associated with $240 and $256 PMPM reductions in total cost of care at 12 months, respectively (−$230 and −$189 PMPM over 24 months; all p < 0.001). Among adults with T2D, savings were driven by reduced inpatient visits and deprescription of sodium-glucose cotransporter 2 (SGLT2) inhibitors (66.8% reduction from baseline cost), sulfonylureas (51.7%), insulin (43.9%), and glucagon-like peptide-1s (GLP-1s) (32.2%). Among adults without T2D and with obesity, reductions accrued across all cost categories. Conclusions In this large, real-world analysis, enrollment in a comprehensive nutrition-first digital care model was associated with reductions in healthcare costs and utilization over 12 and 24 months, with prescription medication cost reductions emerging within the first quarter of treatment among adults with T2D. Together with prior evidence demonstrating clinical effectiveness, these findings suggest that comprehensive digital nutritional care models can generate meaningful economic value.

9 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
PSPriya Shanmugam
Priya Shanmugam
MBMolly Bair
Molly Bair
EPEmma Pendl-Robinson
Emma Pendl-Robinson
XHXindi Cindy Hu
Xindi Cindy Hu
With hundreds of millions of COVID-19 infections to date, a considerable portion of the population has developed or will develop long COVID. Understanding the prevalence, risk factors, and healthcare costs of long COVID can be of significant societal importance. To investigate the utility of large-scale electronic health record (EHR) data in identifying and predicting long COVID, we analyzed a sample of 1.23 million participants from the National COVID Cohort Collaborative (N3C), a longitudinal EHR data repository from 80 sites in the US with over 8 million COVID-19 patients. We characterized the prevalence of long COVID using a few different types of definitions to illustrate their relative strengths and weaknesses. Then we developed machine learning models to predict the risk of developing long COVID using demographic factors and comorbidity in the EHR. The risk factors for long COVID include patient age; sex; smoking status; and comorbidities characterized by the Charlson Comorbidity Index (CCI). We were able to predict three types of long COVID with low to moderate levels of accuracy (AUC 0.599 – 0.734). We found that age and CCI were most predictive of long COVID diagnosis. Ongoing work includes applying the fair machine learning framework to the long COVID predictive models. We are implementing fairness and bias mitigation methods to model fitting through the following steps, selecting fairness metrics, preparing data and model, evaluating fairness metrics, applying bias mitigation methods to the dataset, and comparing model results and fairness metrics before and after the mitigation. The objective is to achieve equalized odds, a statistical notion that ensures classification algorithms do not discriminate against protected groups (such as sex and race/ethnicity). Results from the fairness-based machine learning will be included in the conference presentation.

29 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PSPriya V. Shanmugam
Priya V. Shanmugam
CRCaroline G.P. Roberts
Caroline G.P. Roberts
Shaminie AthinarayananShaminie Athinarayanan
Shaminie Athinarayanan
AWAdam J. Wolfberg
Adam J. Wolfberg
SRStephen Raskin
Stephen Raskin
FLFrancisco Lopez-Jimenez
Francisco Lopez-Jimenez
Importance: Carbohydrate-reduced nutrition improves multiple metabolic risk factors, but its influence on long-term cardiovascular (CV) outcomes remains uncertain. Objective: To evaluate the impact of an individualized telemedicine nutrition therapy on the incidence of CV events. Design: Claims-based cohort study of adults with type 2 diabetes or obesity receiving telemedicine nutrition therapy versus a propensity score matched control group between January 1, 2016 and June 1, 2025, with a median follow-up of approximately two years. Setting: The intervention cohort, a US-based nationwide digital health clinic, received individualized telemedicine nutrition and clinical care. The matched control cohort was derived from a commercial claims database. Participants: Adults with type 2 diabetes or obesity and no CV events one year prior to index date. Exposure: Individualized nutrition therapy (INT) program combining telemedicine clinical care and carbohydrate-reduced nutrition counseling. Main Outcomes and Measures: Four prespecified primary outcomes included 1) 3-point major adverse CV events (MACE), defined as nonfatal myocardial infarction, nonfatal stroke, or death from any cause; 2) 6-point MACE, adding percutaneous coronary intervention, hospitalization for heart failure or unstable angina; 3) all new-onset CV events; and 4) new-onset hypertension. Secondary outcomes included all-cause mortality, and safety outcomes related to arrhythmias. Results: In 4,877 participants in each cohort (mean age, 51 [SD 9.5] years; 2,939 [60.3%] female), INT was associated with reduced risk of all primary outcomes. Incidence per 1,000 person-years was 4.1 vs 9.3 for MACE-3, 5.7 vs 10.8 for MACE-6, 27.7 vs 36.9 for all new onset CV disease, and 41.8 vs 49.3 for new-onset hypertension. Hazard ratios were 0.44 (95% CI, 0.29-0.65; P <0.001) for MACE-3, 0.52 (95% CI, 0.37-0.73; P <0.001) for MACE-6, 0.70 (95% CI, 0.59-0.82; P <0.001) for all CV disease, and 0.81 (95% CI, 0.70-0.93; P <0.001) for new-onset hypertension. Conclusions and Relevance: Individualized telemedicine nutrition therapy was associated with lower CV event incidence compared to controls, suggesting the intervention may confer cardioprotection. KEY POINTS: Question: What is the impact of an individualized telemedicine nutrition program on cardiovascular events? Findings: In this claims-based cohort study, individuals receiving carbohydrate-reduced nutrition therapy had significantly reduced risk of all primary outcomes compared with matched controls: 56% lower 3-point MACE, 48% lower 6-point MACE, 30% lower risk of all new-onset cardiovascular events, and 19% lower new-onset hypertension. The risk of all-cause mortality was also directionally reduced. Meaning: Telemedicine nutrition therapy was associated with favorable cardiovascular outcomes compared to usual care.

11 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PSPriya V. Shanmugam
Priya V. Shanmugam
RARebecca N. Adams
Rebecca N. Adams
Shaminie AthinarayananShaminie Athinarayanan
Shaminie Athinarayanan
AWAdam J. Wolfberg
Adam J. Wolfberg
JBJeromie Ballreich
Jeromie Ballreich
Structured Importance: Type 2 diabetes and obesity drive substantial morbidity and spending. Rigorous evidence on the impacts of digitally delivered lifestyle interventions on healthcare cost and utilization are critical to assessing their value. Objective: Determine the impact of a telehealth-delivered individualized nutrition therapy (INT) program on per-member-per-month (PMPM) total cost of care and utilization over one and two years. Design: Retrospective propensity score matched difference-in-differences analysis of cost and utilization outcomes over the study period of January 2016–March 2025. Setting: US adults participating in a telehealth T2D and obesity management program. Participants: Enrolled in INT for >1 day or had PCP visit for T2D or obesity during study period; had ≥12 months pre-index and ≥90 days post-index claims coverage (allowing ≤30-day gaps). Final matched sample: 6,580 participants and 6,580 controls (per arm: 3,819 with type 2 diabetes and 2,761 with obesity). Exposures: Telehealth-delivered, continuous care integrating individualized carbohydrate-reduced nutrition support, clinician-guided medication management, health coaching, and remote biometric monitoring. Main Outcomes and Measures: Outcomes included PMPM allowed inpatient, outpatient, and prescription medication costs, inpatient, emergency department, primary care, cardiology, and endocrinology visits. For the T2D cohort, PMPM spending and proportion of days covered for each T2D medication. Results: Among 3,819 adults with T2D and 2,761 adults with obesity, program participation was associated with $240 and $256 PMPM reductions in the total cost of care at 12 months (−$230 and $189 over 24 months, all P<.001). In the T2D cohort, savings were driven by deprescription of SGLT2 inhibitors (66.8% reduction in PMPM cost), sulfonylureas (51.7%), insulin (43.9%), and GLP-1s (32.2%). In the obesity cohort, reductions accrued across inpatient, outpatient and prescription medication settings. Conclusions and Relevance: In this large, real-world analysis, a nutrition-first digital care model was associated with sustained reductions in cost and utilization over 12–24 months, with immediate prescription medication cost reductions in the cohort with T2D and broader savings in the cohort with obesity. Together with prior clinical evidence, these findings suggest alignment of clinical effectiveness and cost reductions of a telehealth-delivered lifestyle intervention. Key points: Question: Is participation in a telehealth-delivered individualized nutrition therapy program associated with changes in healthcare costs and utilization among adults with type 2 diabetes (T2D) or obesity? Findings: In this retrospective cohort study of 13,000 matched adults, participation was associated with lower total cost of care at one year (−$240 and −$256 for adults with T2D and obesity respectively) and over two years (T2D: -$230; obesity: $-189). Among adults with T2D, reductions were driven by inpatient costs and all T2D medications, including GLP-1s. Among adults with obesity, reductions occurred across inpatient, outpatient, and prescription medication costs. Meaning: Telehealth-delivered nutrition therapy may reduce healthcare spending for adults with T2D or obesity.